European Commission approves nivolumab ipilimumab combo
The European Commission has approved nivolumab in combination with low-dose ipilimumab for first-line treatment of patients with intermediate and poor risk advanced... Read More
We would like to invite you to be kept up to date with news from the
charity by signing up to our newsletter. Please enter you email address below.
*By submitting your email address you are agreeing to us contacting you with news and appeals from Kidney Cancer
UK & Scotland. We will never share any of your information with any third parties.